Nimish P. Shah
CIK: 0001698082
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Sep 9, 2026KRSA
Korsana Biosciences, Inc.
Award(A)DirectStock Option (Right to Buy)
48.4K shares- - Sep 3, 2026APGE
Apogee Therapeutics, Inc.
Disposition(D)Indirect1.8M shares at avg. $135.11$236.4M - Jun 9, 2026APGE
Apogee Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
7.7K shares- - Oct 10, 2025APGE
Apogee Therapeutics, Inc.
Purchase(P)IndirectPre-Funded Warrants (Right to Buy)
365.9K shares at avg. $41.00- - Jun 17, 2025APGE
Apogee Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
14.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 9, 2026 |  KRSA Korsana Biosciences, Inc. | Award(A) Stock Option (Right to Buy) | 48,445 | - | - | Direct |
| Sep 3, 2026 |  APGE Apogee Therapeutics, Inc. | Disposition(D) | 1,750,000 | $135.11 | $236,442,500 | Indirect |
| Jun 9, 2026 | APGE Apogee Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 7,657 | - | - | Direct |
| Oct 10, 2025 | APGE Apogee Therapeutics, Inc. | Purchase(P) Pre-Funded Warrants (Right to Buy) | 365,853 | $41.00 | - | Indirect |
| Jun 17, 2025 | APGE Apogee Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 14,461 | - | - | Direct |
1-5 of 5 transactions
About Shah Nimish P
Shah Nimish P (SEC CIK 0001698082) files insider reports with the SEC as Director of Korsana Biosciences, Inc. (KRSA) and Director of Apogee Therapeutics, Inc. (APGE).
Signal8 holds 6 ownership filings by Shah Nimish P (1 Form 3, 5 Form 4), filed between Jun 20, 2025 and Sep 10, 2026. Those filings report 5 transactions, from Jun 17, 2025 to Sep 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Shah Nimish P's filings is in WALTHAM, MA.
Recent filings by Shah Nimish P
- Sep 9, 2026: Grant or award of KRSA derivative securities (Form 4, code A).
- Sep 3, 2026: Disposition to issuer transaction of APGE shares (Form 4, code D).
- Jun 9, 2026: Grant or award of APGE derivative securities (Form 4, code A).
- Oct 10, 2025: Open-market purchase of APGE derivative securities (Form 4, code P).
- Jun 17, 2025: Grant or award of APGE derivative securities (Form 4, code A).
Other insiders filing for Korsana Biosciences, Inc. (KRSA)
- Pernice Michelle Patricia, Director
- Fairmount Funds Management LLC, Director
- Gottesdiener Andrew, Director
- Violin Jonathan
- Leoni Matthew James, Chief Medical Officer
- HENSON HEIDI, Director